Cargando…

AR mRNA stability is increased with AR-antagonist resistance via 3′UTR variants

Advanced prostate cancer is often treated with AR antagonists which target the androgen receptor (AR) on which the growth of the tumour depends. Prostate cancer often develops AR-antagonist resistance via a plethora of mechanisms, many of which are as yet unknown, but it is thought that AR upregulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dart, D A, Ashelford, K, Jiang, W G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933836/ https://www.ncbi.nlm.nih.gov/pubmed/31778359 http://dx.doi.org/10.1530/EC-19-0340

Ejemplares similares

Regulation of AR mRNA translation in response to acute AR pathway inhibition
por: Somasekharan, Syam Prakash, et al.
Publicado: (2021)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Combined Therapy of A(1)AR Agonists and A(2A)AR Antagonists in Neuroinflammation
por: Marucci, Gabriella, et al.
Publicado: (2021)

BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability
por: Kuo, P-C, et al.
Publicado: (2015)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

$^{43}$Ar and $^{44}$Ar
por: Hudis, J, et al.
Publicado: (1970)

$^{43}Ar$ and $^{44}Ar$
por: Hudis, J, et al.
Publicado: (1970)

To Be(Ar) Or Not to Be(Ar) – Jones Dilemma?
por: Andrews, Nicholas A., et al.
Publicado: (2022)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Glucocorticoids increase amylase mRNA levels, secretory organelles, and secretion in pancreatic acinar AR42J cells
Publicado: (1985)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023)

GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation
por: Su, Bing, et al.
Publicado: (2019)

Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells
por: Rana, Manjul, et al.
Publicado: (2021)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

β2AR Antagonists and β2AR Gene Deletion Both Promote Skin Wound Repair Processes
por: Pullar, Christine E, et al.
Publicado: (2012)

The “C3aR Antagonist” SB290157 is a Partial C5aR2 Agonist
por: Li, Xaria X., et al.
Publicado: (2021)

Emerging proteins involved in castration-resistant prostate cancer via the AR-dependent and AR-independent pathways (Review)
por: Feng, Kangle, et al.
Publicado: (2023)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

Cheminformatics analysis of the AR agonist and antagonist datasets in PubChem
por: Hao, Ming, et al.
Publicado: (2016)

Ár njöt'i ar hai = El color de la tierra
Publicado: (2014)

Cytoplasmic switch of ARS2 isoforms promotes nonsense-mediated mRNA decay and arsenic sensitivity
por: Mesa-Perez, Monica, et al.
Publicado: (2022)

The mass of $^{32}Ar$ and $^{33}Ar$ for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

Masses of 32Ar and 33Ar for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction
por: Xu, Defeng, et al.
Publicado: (2017)

Determination of $^{44}Ar$(n,$\gamma$)$^{45}$Ar, and $^{46}$Ar(n,$\gamma$)$^{47}$Ar reaction rates by (d,p) transfer reactions
por: Sorlin, O, et al.
Publicado: (2002)

ARS Leptogenesis
por: Drewes, M., et al.
Publicado: (2017)

Ars melancholiae
por: Weiss, Silvius Leopold, 1686-1750
Publicado: (1994)

Ars Obstetrica
por: Armytage, V. B. Green
Publicado: (1930)

Ars Gynæcologica
por: Green-Armytage, V. B.
Publicado: (1930)

Ars Obstetrica
por: Umachigi, V. S.
Publicado: (1930)

Ars Longa
Publicado: (1893)

Boutique neutrons advance (40)Ar/(39)Ar geochronology
por: Rutte, Daniel, et al.
Publicado: (2019)

Author Correction: Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells
por: Rana, Manjul, et al.
Publicado: (2021)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway
por: Liu, Zhengfang, et al.
Publicado: (2021)

Beitrag des BfArM zur Potenzialentfaltung der Digitalisierung im Gesundheitswesen – digital readiness@BfArM
por: Broich, Karl, et al.
Publicado: (2021)

Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_p18i0epnr1pahiram9fav22bd5